MX2018005461A - Metodos para tratar cancer usando compuestos de pirimidina y piridina con actividad inhibidora de tirosina cinasa de bruton. - Google Patents

Metodos para tratar cancer usando compuestos de pirimidina y piridina con actividad inhibidora de tirosina cinasa de bruton.

Info

Publication number
MX2018005461A
MX2018005461A MX2018005461A MX2018005461A MX2018005461A MX 2018005461 A MX2018005461 A MX 2018005461A MX 2018005461 A MX2018005461 A MX 2018005461A MX 2018005461 A MX2018005461 A MX 2018005461A MX 2018005461 A MX2018005461 A MX 2018005461A
Authority
MX
Mexico
Prior art keywords
pyrimidine
treating cancer
methods
pyridine compounds
inhibitory activity
Prior art date
Application number
MX2018005461A
Other languages
English (en)
Inventor
R Huck Bayard
M Goodstal Samantha
Gimmi-Mckim Claude
Original Assignee
Merck Patent Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Patent Gmbh filed Critical Merck Patent Gmbh
Publication of MX2018005461A publication Critical patent/MX2018005461A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/69—Boron compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Abstract

La presente invención proporciona métodos para el tratamiento del cáncer usando compuestos de pirimidina y piridina que son inhibidores de tirosina cinasa de Bruton (BTK, por sus siglas en inglés).
MX2018005461A 2015-11-04 2016-11-04 Metodos para tratar cancer usando compuestos de pirimidina y piridina con actividad inhibidora de tirosina cinasa de bruton. MX2018005461A (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201562250575P 2015-11-04 2015-11-04
US201662296143P 2016-02-17 2016-02-17
US201662341189P 2016-05-25 2016-05-25
PCT/US2016/060508 WO2017079542A1 (en) 2015-11-04 2016-11-04 Methods for treating cancer using pyrimidine and pyridine compounds with btk inhibitory activity

Publications (1)

Publication Number Publication Date
MX2018005461A true MX2018005461A (es) 2018-08-01

Family

ID=57442803

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2018005461A MX2018005461A (es) 2015-11-04 2016-11-04 Metodos para tratar cancer usando compuestos de pirimidina y piridina con actividad inhibidora de tirosina cinasa de bruton.
MX2021015826A MX2021015826A (es) 2015-11-04 2018-04-30 Metodos para tratar cancer usando compuestos de pirimidina y piridina con actividad inhibidora de tirosina cinasa de bruton.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2021015826A MX2021015826A (es) 2015-11-04 2018-04-30 Metodos para tratar cancer usando compuestos de pirimidina y piridina con actividad inhibidora de tirosina cinasa de bruton.

Country Status (22)

Country Link
US (3) US20170119766A1 (es)
EP (2) EP3371165B1 (es)
JP (3) JP6913100B2 (es)
KR (1) KR20180073599A (es)
CN (1) CN108779095A (es)
AU (3) AU2016349584B9 (es)
BR (1) BR112018007604B1 (es)
CA (1) CA3001735A1 (es)
DK (1) DK3371165T3 (es)
ES (1) ES2912059T3 (es)
HU (1) HUE058323T2 (es)
IL (2) IL293093B1 (es)
LT (1) LT3371165T (es)
MX (2) MX2018005461A (es)
NZ (1) NZ741293A (es)
PL (1) PL3371165T3 (es)
RS (1) RS63146B1 (es)
RU (2) RU2765154C2 (es)
SG (2) SG10202005292UA (es)
SI (1) SI3371165T1 (es)
TW (2) TW202320784A (es)
WO (1) WO2017079542A1 (es)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ741293A (en) * 2015-11-04 2023-06-30 Merck Patent Gmbh Methods for treating cancer using pyrimidine and pyridine compounds with btk inhibitory activity
BR112018007517B1 (pt) * 2015-11-17 2023-09-26 Merck Patent Gmbh Uso decompostos de pirimidina e piridina com atividade inibidora de btk para preparar medicamentos para tratar esclerose múltipla
WO2018204532A1 (en) * 2017-05-03 2018-11-08 Vivace Therapeutics, Inc. Non-fused tricyclic compounds
WO2019243223A1 (en) 2018-06-19 2019-12-26 Merck Patent Gmbh Novel crystalline forms of 1-(4-{[6-amino-5-(4-phenoxy-phenyl)-pyrimidin-4-ylamino]-methyl}-4-fluoro-piperidin-1-yl)-propenone, salt forms thereof, and processes to obtain
US20210308140A1 (en) 2018-07-25 2021-10-07 Novartis Ag Nlrp3 inflammasome inhibitors
AR119731A1 (es) 2019-05-17 2022-01-05 Novartis Ag Inhibidores del inflamasoma nlrp3
UY39377A (es) 2020-08-14 2022-03-31 Novartis Ag Derivados de espiropiperidinilo sustituidos con heteroarilo y usos farmacéuticos de los mismos
CN112250666B (zh) * 2020-10-09 2022-01-14 广东东阳光药业有限公司 取代的嘧啶类化合物及其用途
TW202304889A (zh) * 2021-04-03 2023-02-01 大陸商海南耀臻生物醫藥科技有限公司 作為fgfr抑制劑的雜環化合物及其應用
US11866421B2 (en) 2021-05-31 2024-01-09 Epigen Biosciences, Inc. Pyrimidine and pyridine amine compounds and usage thereof in disease treatment
WO2023247774A1 (en) 2022-06-24 2023-12-28 Merck Patent Gmbh Treatment regimen for autoimmune diseases and inflammatory diseases
TW202406550A (zh) 2022-08-03 2024-02-16 瑞士商諾華公司 Ｎｌｒｐ３炎性小體抑制劑

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19649896A1 (de) * 1996-12-02 1998-06-04 Henkel Kgaa Geformte Seifenprodukte
TW520362B (en) * 1996-12-05 2003-02-11 Amgen Inc Substituted pyrimidine compounds and pharmaceutical composition comprising same
EP2786995A1 (en) * 2004-03-30 2014-10-08 Vertex Pharmaceuticals Incorporated Azaindoles useful as inhibitors of JAK and other protein kinases
JP2011500823A (ja) * 2007-10-22 2011-01-06 グラクソスミスクライン・リミテッド・ライアビリティ・カンパニー Ｐｉ３キナーゼ阻害物質としてのピリドスルホンアミド誘導体
CL2009001152A1 (es) * 2008-05-13 2009-10-16 Array Biopharma Inc Compuestos derivados de n-(4-(cicloalquilo nitrogenado-1-il)-1h-pirrolo[2,3-b]piridin-3-il)amida, inhibidores de cinasa; proceso de preparacion; composicion farmaceutica; y su uso para el tratamiento de una enfermedad proliferativa.
JP2014517016A (ja) * 2011-06-10 2014-07-17 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｂｔｋ阻害活性を有するピリミジンおよびピリミジン化合物の組成物と製造方法
TW201414734A (zh) * 2012-07-10 2014-04-16 Takeda Pharmaceutical 氮雜吲哚衍生物
WO2014093230A2 (en) * 2012-12-10 2014-06-19 Merck Patent Gmbh Compositions and methods for the production of pyrimidine and pyridine compounds with btk inhibitory activity
WO2014151620A1 (en) * 2013-03-14 2014-09-25 Boehringer Ingelheim International Gmbh 5-thiazolecarboxamide dervatives and their use as btk inhibitors
MY184292A (en) * 2013-09-22 2021-03-30 Sunshine Lake Pharma Co Ltd Substituted aminopyrimidine compounds and methods of use
GB201404987D0 (en) * 2014-03-20 2014-05-07 Redx Pharma Ltd Compounds
NZ741293A (en) * 2015-11-04 2023-06-30 Merck Patent Gmbh Methods for treating cancer using pyrimidine and pyridine compounds with btk inhibitory activity
BR112018007517B1 (pt) * 2015-11-17 2023-09-26 Merck Patent Gmbh Uso decompostos de pirimidina e piridina com atividade inibidora de btk para preparar medicamentos para tratar esclerose múltipla

Also Published As

Publication number Publication date
RS63146B1 (sr) 2022-05-31
HUE058323T2 (hu) 2022-07-28
LT3371165T (lt) 2022-05-10
SG10202005292UA (en) 2020-07-29
US11491153B2 (en) 2022-11-08
IL293093A (en) 2022-07-01
KR20180073599A (ko) 2018-07-02
AU2021211982B2 (en) 2023-03-02
US20210244736A1 (en) 2021-08-12
JP7295169B2 (ja) 2023-06-20
BR112018007604A2 (pt) 2018-10-23
IL258979A (en) 2018-06-28
TW202320784A (zh) 2023-06-01
CN108779095A (zh) 2018-11-09
RU2018120153A (ru) 2019-12-05
AU2021211982A1 (en) 2021-08-26
AU2016349584A1 (en) 2018-04-26
JP2021165308A (ja) 2021-10-14
MX2021015826A (es) 2022-02-03
EP3371165A1 (en) 2018-09-12
SG11201802927VA (en) 2018-05-30
RU2022100782A (ru) 2022-02-03
SI3371165T1 (sl) 2022-05-31
JP2018532805A (ja) 2018-11-08
NZ741293A (en) 2023-06-30
CA3001735A1 (en) 2017-05-11
WO2017079542A1 (en) 2017-05-11
AU2016349584B2 (en) 2021-05-13
TW201722430A (zh) 2017-07-01
EP3371165B1 (en) 2022-01-26
RU2018120153A3 (es) 2020-03-05
IL258979B (en) 2022-06-01
AU2023203377A1 (en) 2023-06-29
AU2016349584B9 (en) 2021-06-03
JP6913100B2 (ja) 2021-08-04
JP2023105214A (ja) 2023-07-28
TWI783915B (zh) 2022-11-21
RU2765154C2 (ru) 2022-01-26
IL293093B1 (en) 2024-03-01
EP4014977A1 (en) 2022-06-22
US20170119766A1 (en) 2017-05-04
DK3371165T3 (da) 2022-05-02
ES2912059T3 (es) 2022-05-24
PL3371165T3 (pl) 2022-05-02
US20200206224A1 (en) 2020-07-02
BR112018007604B1 (pt) 2022-08-16

Similar Documents

Publication Publication Date Title
MX2021015826A (es) Metodos para tratar cancer usando compuestos de pirimidina y piridina con actividad inhibidora de tirosina cinasa de bruton.
PH12018500736A1 (en) Methods for treating multiple sclerosis using pyrimidine and pyridine compounds with btk inhibitory activity
PH12018500792A1 (en) Benzolactam compounds as protein kinase inhibitors
PH12018501268A1 (en) Compounds useful as kinase inhibitors
PH12018501084A1 (en) Heterocyclic compounds as immunomodulators
EA201692511A1 (ru) Комбинированное лечение ингибиторами глутаминазы
EA201990187A1 (ru) Антипролиферационные средства на основе пиримидина
MX2019007243A (es) Inhibidores de ectonucleotidasa y metodos de uso de los mismos.
IL255831A (en) Inhibitors of bruton's tyrosine kinase
PH12018500587A1 (en) Pyrazolopyrimidine derivatives as btk inhibitors for the treatment of cancer
EA201791133A1 (ru) Ингибиторы erk
MX2019001125A (es) Inhibidores de cinasa macrociclica.
NZ718190A (en) Substituted quinazolines for inhibiting kinase activity
MX2019001471A (es) Anticuerpos anti-siglec-7 para el tratamiento del cancer.
MX2017004128A (es) Derivados de diarilurea como inhibidores de quinasa p38.
ZA201805439B (en) Bruton's tyrosine kinase inhibitors
PH12020500072A1 (en) Heterocyclic inhibitors of atr kinase
MX2020006365A (es) Quinazolinonas como inhibidores de poli(adenosin difosfato-ribosa)polimerasa 14 (parp14).
ZA201903694B (en) Inhibitors of bruton's tyrosine kinase
MX2017013875A (es) Ciertos inhibidores de la proteína quinasa.
MX2016009655A (es) Metodos novedosos para el tratamiento del cancer.
NZ740817A (en) Pcna inhibitors
MX2018005987A (es) Compuestos heterociclicos para el tratamiento de enfermedades.
MX2018013573A (es) Ciertos inhibidores de la proteína cinasa.
MX367707B (es) Composiciones para uso en la prevencion y el tratamiento de enfermedades neurodegenerativas y dolor.